SNDX

Over the past six months (April-October 2026), Syndax Pharmaceuticals experienced several stock events. In April 2026, the company reported a Q1 loss and missed revenue estimates. June 2026 saw the presentation of new data for Revuforj and a $243 million private placement for convertible senior notes. In July 2026, Syndax highlighted late-stage programs and new pipeline assets at an R&D event, including expansion plans for Revuforj and Niktimvo, and two new pipeline assets for non-small cell lung cancer and myelofibrosis. August 2026 brought Q2 financial results, with revenue surging 92% year-over-year to $72.8 million driven by Revuforj and Niktimvo sales, though it missed analyst consensus estimates for both revenue and earnings per share; the stock gained 4.4% post-earnings, and State Street Corporation disclosed a 6.4% holding. In September 2026, Syndax announced participation in investor conferences, and the stock price decreased by 15.3% from September 8 to October 8, 2026. October 2026 saw the company report inducement grants, and analyst sentiment remained a 'Moderate Buy' despite the stock being below its moving averages, with JPMorgan Chase & Co. lowering its price target but maintaining an 'overweight' rating.